SOURCE: The Bedford Report

The Bedford Report

July 07, 2011 08:16 ET

Zalicus and Cyclacel Show Promising Pipelines

The Bedford Report Provides Equity Research on Zalicus and Cyclacel

NEW YORK, NY--(Marketwire - Jul 7, 2011) - Recent studies suggest that the FDA has begun approving drugs at a faster rate. This is welcome news for biotechnology companies -- many of which struggle to secure the necessary capital to maintain operations. The Bedford Report examines the outlook for companies in the Healthcare Sector and provides equity research on Zalicus, Inc. (NASDAQ: ZLCS) and Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC). Access to the full company reports can be found at:

Studies from the Friends of Cancer Research advocacy group find that new cancer drugs are approved in just six months on average in the United States -- half the time it takes for the same drugs to be approved in Europe. "When we realized we were correct, we thought, 'No one is going to believe us because this goes against urban legend,'" said Ellen V. Sigal, chairwoman and founder of Friends of Cancer Research.

User fees from the Prescription Drug User Fee Act of 1992 have helped provide the FDA with resources to shorten drug review times. The Act is up for reauthorization next year, and the Friends of Cancer Research argue that the speed of drug review times might not be as high a priority as achieving other objectives in advance regulatory science.

The Bedford Report releases investment research on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

While Zalicus is mostly known for its focus on the treatment of pain and inflammation, ZLCS and Novartis presently have a strategic alliance focused on the discovery of novel anti-cancer combinations. The collaboration explores combination effects in cell lines representing a broad spectrum of cancers to provide a robust and systematic understanding of combination therapy opportunities. Under the agreement, Zalicus received a $4 million upfront payment and funding for research support for two years.

Cyclacel is engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. Shares of the company took a recent tumble after the biotech firm said it plans to offer 7.62 million securities units priced at $1.36 a share. The net proceeds from the offering will be used for funding the Company's SEAMLESS pivotal Phase 3 trial of its leading drug, sapacitabine, and general corporate purposes.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information